Friedreich Ataxia Nerve Ultrasund
NCT07508631 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 14
Last updated 2026-04-02
Summary
"Friedreich ataxia is the most common inherited autosomal recessive ataxia. It is caused by a GAA repeat expansion in the frataxin gene on chromosome 9q21.11. Symptoms usually begin in childhood, typically between 9 and 13 years of age. The disease leads to progressive damage of the nervous system and the heart, as well as multisystem involvement of various degrees, leading to diabetes, vision and hearing loss and scoliosis. Over time, most patients lose the ability to walk and require a wheelchair, often by their mid-twenties. The severity and progression of the disease can vary depending on various factors such as the age at onset and the size of the GAA triplet expansion.
Traditionally, Friedreich ataxia has been considered a disorder primarily affecting nerve cells, also called neuronopathy. However, recent studies using ultrasound imaging of peripheral nerves have shown that some nerves may appear enlarged, particularly in the upper limbs. This is in contrast with findings usually observed in other neuronopathies, where peripheral nerves tend to become thinner.
The aim of this study is to use nerve ultrasound to better understand changes in intraneural vascularization and nerve in patients with Friedreich ataxia. In particular, we assess the presence of intraneural blood flow within the nerves using a high-resolution ultrasound technique.
The study includes 13 patients with genetically confirmed Friedreich ataxia who are followed at the Neurogenetics Competence Center of Nice University Hospital. Ultrasound examinations are performed on the median and ulnar nerves at standardized locations: for median nerve at wrist, forearm (10 cm from the distal wrist crease), antecubital fossa, mid-arm and axilla; for ulnar nerve at the wrist, forearm (10 cm from the pisiform bone), at the elbow (5 cm below and above the elbow), mid-arm and axilla; the brachial plexus is measured at level C5, C6, C7.
In addition to vascularization, we also measure nerve size (cross-sectional area) and evaluate internal nerve structure.
This study aims to improve understanding of nerve involvement in Friedreich ataxia and to explore whether ultrasound could provide useful markers of disease severity."
Conditions
- Friedreich Ataxia
Interventions
- DIAGNOSTIC_TEST
-
Nerve ultrasound - routine exam
Nerve ultrasound is a widely used imaging modality in clinical practice. It allows for the measurement of nerve cross-sectional area and provides detailed visualization of internal fascicular architecture and vascularization. These features can offer indirect information about underlying nerve pathology, such as inflammation or structural damage. Reference values have been established for different segments of the median and ulnar nerves, as well as for the brachial plexus
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Nice
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-01
- Primary Completion
- 2026-04-30
- Completion
- 2026-04-30
Countries
- France
Study Locations
More Related Trials
-
Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia
NCT07013292 ·Status: RECRUITING
-
Safety Study of Idebenone to Treat Friedreich's Ataxia
NCT00015808 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Nicotinamide in Friedreich's Ataxia
NCT01589809 ·Status: UNKNOWN ·Phase: PHASE2
-
Iron-Chelating Therapy and Friedreich Ataxia
NCT00224640 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia
NCT00530127 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia
NCT00078481 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia
NCT00897221 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of Epoetin Alfa in Friedreich Ataxia
NCT01493973 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Effects of Calcitriol's in the Neurological Symptoms of Friedreich's Ataxia Patients
NCT04801303 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia
NCT00631202 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients
NCT02035020 ·Status: COMPLETED ·Phase: PHASE2
-
Idebenone to Treat Friedreich's Ataxia
NCT00229632 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
NCT04102501 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia
NCT01016366 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
NCT03214588 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
NCT07180355 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
NCT06623890 ·Status: RECRUITING
-
A First in Human Study of RT001 in Patients With Friedreich's Ataxia
NCT02445794 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
NCT04921930 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia
NCT01921868 ·Status: UNKNOWN ·Phase: NA
-
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
NCT06874010 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
NCT06054893 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
NCT05573698 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients
NCT03917225 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia
NCT00824512 ·Status: COMPLETED ·Phase: PHASE2